Email this article On the possible prospects for the use of cannabis for medical purposes
- Authors: Titulova A.P.1, Grebneva N.Y.1
-
Affiliations:
- Military Medical Academy
- Issue: Vol 42, No 2 (2023)
- Pages: 177-184
- Section: Reviews
- URL: https://journal-vniispk.ru/RMMArep/article/view/316032
- DOI: https://doi.org/10.17816/rmmar340773
- ID: 316032
Cite item
Full Text
Abstract
The use of cannabis as a therapeutic agent in medical practice in the Russian Federation is one of the current and discussed issues. Cannabis is the tops of the eponymous plant of the genus cannabis (Cannabis sp.) with flowers or fruits (with the exception of seeds and leaves, if they are not accompanied by tops), from which resin has not been extracted, no matter what name they are designated, as well as other products from this plant. More than 400 different chemical compounds have been found in the chemical composition of the above-ground part of cannabis, of which 61 are cannabinoids. Among cannabinoids the most studied are tetrahydrocannabinol, cannabidiol and cannabinol. In Russia, the use of cannabis as a medicine is not currently permitted due to governmental and industrial prohibitions, which limits clinical research to determine the safety and effectiveness of its use in medical practice. At the same time, a number of countries have legalized the use of cannabis for medical purposes. Cannabis-based prescription medications (dronabinol, nabiximols, nabilon, epidiolex) are known to be used abroad to treat various medical conditions. The issue of the use of cannabis for medical purposes on the territory of the Russian Federation requires further elaboration, taking into account the legal and regulatory framework.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Anastasia P. Titulova
Military Medical Academy
Email: tillsledy@gmail.com
ORCID iD: 0009-0006-3689-4837
SPIN-code: 1819-8873
preparator of the acad. E.N. Pavlovsky Biology Department
Russian Federation, Saint PetersburgNatal'ya Yu. Grebneva
Military Medical Academy
Author for correspondence.
Email: n.grebneva@gmail.com
ORCID iD: 0009-0002-2084-9485
SPIN-code: 3236-0502
Ph.D. (Pharmaceuticals), Lecturer at the Pharmacy Department
Russian Federation, Saint PetersburgReferences
- Borgelt LM, Franson KL, Nussbaum AM, et al. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195–209. doi: 10.1002/phar.1187
- Devane W, Hanus L, Breuer A, et. al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949. doi: 10.1126/science.1470919
- Devane WA, Dysarz FA 3rd, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–613.
- Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441): 61–65. doi: 10.1038/365061a0
- Shao Z, Yin J, Chapman K, et. al. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016;540(7634): 602–606. doi: 10.1038/nature20613
- Hua T, Vemuri K, Nikas SP, et al. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 2017;547(7664): 468–471. doi: 10.1038/nature23272
- Pertwee RG. Different CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008;153(2):199–215. doi: 10.1038/sj.bjp.0707442
- Russo EB, Burnett A, Hall B, et al. Agonist properties of cannabidiol against 5-HT1a receptors. Neurochemical Research. 2005;30(8):1037–1043.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. doi: 10.1001/jama.2015.6358
- Kathmann M, Flau K, Redmer A, et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006;372(5):354–361. doi: 10.1007/s00210-006-0033-x
- Perucca E, Bialer M. Critical aspects affecting oral cannabidiol bioavailability and metabolic excretion and related clinical implications. CNS drugs. 2020;34(8):795–800.
- Scuderi C, Filippis DD, Iuvone T, et al. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res. 2009;23:597–602. doi: 10.1002/ptr.262523
- Zuardi A, Crippa J, Hallak J, et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol. 2009;23(8):979–983 doi: 10.1177/0269881108096519
- Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306–307. doi: 10.1192/bjp.bp.107.046649
- Whiting PF, Wolff RF, Deshpande S, et. al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. doi: 10.1001/jama.2015.6358
- Turgeman I, Bar-Sela G. Cannabis use in palliative oncology: a review of the evidence for popular indications. Isr Med Assoc J. 2017;19:85–88.
- Nguyen LC, Yang D, Dann C, et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Science advances. 2022;8:6110.
- Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;(4):CD005175. doi: 10.1002/14651858.CD005175.pub3
- Larionova EV, Shuvalova AA. Modern studies of the influence of tetrahydrocannabinol on higher mental functions. Psychology. Journal of the Higher School of Economics. 2017;14(1):189–199. doi: 10.17323/1813-8918.2017.1.189.199
- Zirpel B, Stehle F, Kayser O. Production of Δ9-tetrahydrocannabinolic acid from cannabigerolic acid by whole cells of Pichia (Komagataella) pastoris expressing Δ9-tetrahydrocannabinolic acid synthase from Cannabis sativa L. Biotechnol Lett. 2015;37(9):1869–1875. doi: 10.1007/s10529-015-1853-x
Supplementary files
